PUBLISHER: Bizwit Research & Consulting LLP | PRODUCT CODE: 1566414
PUBLISHER: Bizwit Research & Consulting LLP | PRODUCT CODE: 1566414
Global Retinal Vein Occlusion Treatment Market Size Study, by Disease Type, by Treatment, by End-user and Regional Forecasts 2022-2032
The global Retinal Vein Occlusion (RVO) treatment market was valued at approximately USD 2.65 billion in 2023 and is projected to exhibit a compound annual growth rate (CAGR) of 6.92% over the forecast period 2024-2032. Retinal Vein Occlusion, a significant cause of vision loss, demands timely and effective treatment strategies to prevent severe complications. Treatment modalities include anti-VEGF injections, corticosteroids, and laser therapies, aimed at reducing retinal swelling and preventing the abnormal proliferation of blood vessels, which are common in this condition. These treatments are crucial in maintaining visual acuity and preventing the progression of RVO-related complications like macular edema and neovascular glaucoma.
The aging global population is a primary driver of the RVO treatment market. As the population ages, the incidence of RVO increases due to the natural degeneration of retinal blood vessels, necessitating effective treatment solutions. Moreover, ongoing advancements in therapeutic technologies, particularly in the development of anti-VEGF drugs such as Ranibizumab and Aflibercept, are propelling market growth. These advancements have significantly enhanced treatment outcomes, offering hope to millions of patients worldwide. Additionally, the growing awareness of eye health and the importance of early diagnosis is driving the market, as more individuals seek timely intervention to manage and treat RVO effectively. Also, emerging markets present substantial growth opportunities, particularly due to the rising prevalence of diabetes and hypertension-major risk factors for RVO. As healthcare infrastructure continues to improve in these regions, the demand for advanced RVO treatments is expected to increase. Moreover, the development of biologics and personalized medicine holds promise for further market expansion, as these approaches allow for more tailored and effective treatments. However, the market faces challenges, notably the high cost of RVO treatments, particularly biologics. These treatments are often expensive, making them inaccessible to patients in low-income regions. The affordability issue is further exacerbated by inadequate insurance coverage and reimbursement challenges, which can limit patient access to these essential treatments.
In 2023, North America dominated the global RVO treatment market, accounting for a significant share due to its advanced healthcare infrastructure and the high prevalence of eye-related issues. The region's well-regulated healthcare system and the presence of key industry players have also contributed to market growth. On the other hand, Asia Pacific is expected to witness the fastest growth during the forecast period, driven by the increasing adoption of novel therapies and significant investments in healthcare infrastructure in countries like Japan, China, and India.
Major market players included in this report are:
- AbbVie Inc.
- F. Hoffmann-La Roche Ltd.
- Regeneron Pharmaceuticals Inc.
- Taiwan Liposome Company, Ltd.
- Aerie Pharmaceuticals Inc.
- CalciMedica Inc.
- Outlook Therapeutics, Inc.
- Kodiak Sciences Inc.
- Chugai Pharmaceutical Co., Ltd.
- Pfizer Inc.
The detailed segments and sub-segment of the market are explained below:
By Disease Type:
- Central Retinal Vein Occlusion (CRVO)
- Branch Retinal Vein Occlusion (BRVO)
By Treatment:
- Anti-vascular Endothelial Growth Factor (Anti-VEGF)
- Corticosteroid Drugs
- Others
By End-user:
- Hospital & Clinics
- Retail Pharmacy
- Others
By Region:
- North America
- U.S.
- Canada
- Europe
- UK
- Germany
- France
- Spain
- Italy
- ROE
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- RoAPAC
- Latin America
- Brazil
- Mexico
- RoLA
- Middle East & Africa
- Saudi Arabia
- South Africa
- RoMEA
Years considered for the study are as follows:
- Historical year - 2022
- Base year - 2023
- Forecast period - 2024 to 2032
Key Takeaways:
- Market Estimates & Forecast for 10 years from 2022 to 2032.
- Annualized revenues and regional level analysis for each market segment.
- Detailed analysis of geographical landscape with Country level analysis of major regions.
- Competitive landscape with information on major players in the market.
- Analysis of key business strategies and recommendations on future market approach.
- Analysis of competitive structure of the market.
- Demand side and supply side analysis of the market.
Table of Contents
Chapter 1. Global Retinal Vein Occlusion Treatment Market Executive Summary
- 1.1. Global Retinal Vein Occlusion Treatment Market Size & Forecast (2022- 2032)
- 1.2. Regional Summary
- 1.3. Segmental Summary
- 1.3.1. By Disease Type
- 1.3.2. By Treatment
- 1.3.3. By End-user
- 1.4. Key Trends
- 1.5. Recession Impact
- 1.6. Analyst Recommendation & Conclusion
Chapter 2. Global Retinal Vein Occlusion Treatment Market Definition and Research Assumptions
- 2.1. Research Objective
- 2.2. Market Definition
- 2.3. Research Assumptions
- 2.3.1. Inclusion & Exclusion
- 2.3.2. Limitations
- 2.3.3. Supply Side Analysis
- 2.3.3.1. Availability
- 2.3.3.2. Infrastructure
- 2.3.3.3. Regulatory Environment
- 2.3.3.4. Market Competition
- 2.3.3.5. Economic Viability (Consumer's Perspective)
- 2.3.4. Demand Side Analysis
- 2.3.4.1. Regulatory frameworks
- 2.3.4.2. Technological Advancements
- 2.3.4.3. Environmental Considerations
- 2.3.4.4. Consumer Awareness & Acceptance
- 2.4. Estimation Methodology
- 2.5. Years Considered for the Study
- 2.6. Currency Conversion Rates
Chapter 3. Global Retinal Vein Occlusion Treatment Market Dynamics
- 3.1. Market Drivers
- 3.1.1. Aging Population
- 3.1.2. Advancements in Therapeutic Technologies
- 3.1.3. Rising Awareness and Early Diagnosis
- 3.2. Market Challenges
- 3.2.1. High Treatment Costs
- 3.3. Market Opportunities
- 3.3.1. Emerging Markets
- 3.3.2. Biologics and Personalized Medicine
Chapter 4. Global Retinal Vein Occlusion Treatment Market Industry Analysis
- 4.1. Porter's 5 Force Model
- 4.1.1. Bargaining Power of Suppliers
- 4.1.2. Bargaining Power of Buyers
- 4.1.3. Threat of New Entrants
- 4.1.4. Threat of Substitutes
- 4.1.5. Competitive Rivalry
- 4.1.6. Futuristic Approach to Porter's 5 Force Model
- 4.1.7. Porter's 5 Force Impact Analysis
- 4.2. PESTEL Analysis
- 4.2.1. Political
- 4.2.2. Economical
- 4.2.3. Social
- 4.2.4. Technological
- 4.2.5. Environmental
- 4.2.6. Legal
- 4.3. Top investment opportunity
- 4.4. Top winning strategies
- 4.5. Disruptive Trends
- 4.6. Industry Expert Perspective
- 4.7. Analyst Recommendation & Conclusion
Chapter 5. Global Retinal Vein Occlusion Treatment Market Size & Forecasts by Disease Type 2022-2032
- 5.1. Segment Dashboard
- 5.2. Global Retinal Vein Occlusion Treatment Market: Disease Type Revenue Trend Analysis, 2022 & 2032 (USD Billion)
- 5.2.1. Central Retinal Vein Occlusion (CRVO)
- 5.2.2. Branch Retinal Vein Occlusion (BRVO)
Chapter 6. Global Retinal Vein Occlusion Treatment Market Size & Forecasts by Treatment 2022-2032
- 6.1. Segment Dashboard
- 6.2. Global Retinal Vein Occlusion Treatment Market: Treatment Revenue Trend Analysis, 2022 & 2032 (USD Billion)
- 6.2.1. Anti-vascular Endothelial Growth Factor (Anti-VEGF)
- 6.2.2. Corticosteroid Drugs
- 6.2.3. Others
Chapter 7. Global Retinal Vein Occlusion Treatment Market Size & Forecasts by End-user 2022-2032
- 7.1. Segment Dashboard
- 7.2. Global Retinal Vein Occlusion Treatment Market: End-user Revenue Trend Analysis, 2022 & 2032 (USD Billion)
- 7.2.1. Hospital & Clinics
- 7.2.2. Retail Pharmacy
- 7.2.3. Others
Chapter 8. Global Retinal Vein Occlusion Treatment Market Size & Forecasts by Region 2022-2032
- 8.1. North America Retinal Vein Occlusion Treatment Market
- 8.1.1. U.S. Retinal Vein Occlusion Treatment Market
- 8.1.1.1. Disease Type breakdown size & forecasts, 2022-2032
- 8.1.1.2. Treatment breakdown size & forecasts, 2022-2032
- 8.1.1.3. End-user breakdown size & forecasts, 2022-2032
- 8.1.2. Canada Retinal Vein Occlusion Treatment Market
- 8.1.1. U.S. Retinal Vein Occlusion Treatment Market
- 8.2. Europe Retinal Vein Occlusion Treatment Market
- 8.2.1. U.K. Retinal Vein Occlusion Treatment Market
- 8.2.2. Germany Retinal Vein Occlusion Treatment Market
- 8.2.3. France Retinal Vein Occlusion Treatment Market
- 8.2.4. Spain Retinal Vein Occlusion Treatment Market
- 8.2.5. Italy Retinal Vein Occlusion Treatment Market
- 8.2.6. Rest of Europe Retinal Vein Occlusion Treatment Market
- 8.3. Asia-Pacific Retinal Vein Occlusion Treatment Market
- 8.3.1. China Retinal Vein Occlusion Treatment Market
- 8.3.2. India Retinal Vein Occlusion Treatment Market
- 8.3.3. Japan Retinal Vein Occlusion Treatment Market
- 8.3.4. Australia Retinal Vein Occlusion Treatment Market
- 8.3.5. South Korea Retinal Vein Occlusion Treatment Market
- 8.3.6. Rest of Asia Pacific Retinal Vein Occlusion Treatment Market
- 8.4. Latin America Retinal Vein Occlusion Treatment Market
- 8.4.1. Brazil Retinal Vein Occlusion Treatment Market
- 8.4.2. Mexico Retinal Vein Occlusion Treatment Market
- 8.4.3. Rest of Latin America Retinal Vein Occlusion Treatment Market
- 8.5. Middle East & Africa Retinal Vein Occlusion Treatment Market
- 8.5.1. Saudi Arabia Retinal Vein Occlusion Treatment Market
- 8.5.2. South Africa Retinal Vein Occlusion Treatment Market
- 8.5.3. Rest of Middle East & Africa Retinal Vein Occlusion Treatment Market
Chapter 9. Competitive Intelligence
- 9.1. Key Company SWOT Analysis
- 9.2. Top Market Strategies
- 9.3. Company Profiles
- 9.3.1. AbbVie Inc.
- 9.3.1.1. Key Information
- 9.3.1.2. Overview
- 9.3.1.3. Financial (Subject to Data Availability)
- 9.3.1.4. Product Summary
- 9.3.1.5. Market Strategies
- 9.3.2. F. Hoffmann-La Roche Ltd.
- 9.3.3. Regeneron Pharmaceuticals Inc.
- 9.3.4. Aerie Pharmaceuticals Inc.
- 9.3.5. Pfizer Inc.
- 9.3.6. Taiwan Liposome Company, Ltd.
- 9.3.7. CalciMedica Inc.
- 9.3.8. Kodiak Sciences Inc.
- 9.3.9. Chugai Pharmaceutical Co., Ltd.
- 9.3.10. Outlook Therapeutics, Inc.
- 9.3.1. AbbVie Inc.
Chapter 10. Research Process
- 10.1. Research Process
- 10.1.1. Data Mining
- 10.1.2. Analysis
- 10.1.3. Market Estimation
- 10.1.4. Validation
- 10.1.5. Publishing
- 10.2. Research Attributes
